U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula 2K.S
Molecular Weight 110.262
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of POTASSIUM SULFIDE

SMILES

[S--].[K+].[K+]

InChI

InChIKey=DPLVEEXVKBWGHE-UHFFFAOYSA-N
InChI=1S/2K.S/q2*+1;-2

HIDE SMILES / InChI

Molecular Formula HS
Molecular Weight 33.073
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula K
Molecular Weight 39.0983
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://pubchem.ncbi.nlm.nih.gov/compound/sodium_ion | https://www.ncbi.nlm.nih.gov/pubmed/5107832 | https://www.drugs.com/pro/kayexalate.html | https://www.ncbi.nlm.nih.gov/pubmed/2907018

In the last years, the medical application of potassium hydroxide (KOH) is increased. It was found, that topical 5% KOH solution was as effective as CO2 laser in the treatment of female genital warts. There was not any serious complication in the application of KOH solution that could be used as a new treatment for genital warts. 10% KOH is found to be equally effective in the treatment of plane warts compared to 30% TCA with the advantage of faster onset of action and tendency of completely clearing warts with fewer side effects. In addition, potassium hydroxide in phase III of clinical trials for the treatment molluscum contagiosum, which is a non-serious children viral infection.

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
POTASSIUM HYDROXIDE

Approved Use

Used as a softener for nail grooves. Also used as a slide medium in Potassium Hydroxide preparations. Apply to nail in office.

Launch Date

1.27915196E12
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Kayexalate

Approved Use

INDICATION AND USAGE Kayexalate is indicated for the treatment of hyperkalemia.

Launch Date

-3.65299204E11
PubMed

PubMed

TitleDatePubMed
One-electron reduction of chromium(VI) by alpha-lipoic acid and related hydroxyl radical generation, dG hydroxylation and nuclear transcription factor-kappaB activation.
1997 Feb 15
Molecular characterization of a broad selectivity neutral solute channel.
1998 Sep 18
Cloning and functional expression of rAOP9L a new member of aquaporin family from rat liver.
1999 Feb
Inhibition of HIV-1 infection by zinc group metal compounds.
1999 Sep
Aquaporin-1 is expressed by vascular smooth muscle cells and mediates rapid water transport across vascular cell membranes.
1999 Sep-Oct
Role of aquaporin water channels in pleural fluid dynamics.
2000 Dec
Erythrocyte water permeability and renal function in double knockout mice lacking aquaporin-1 and aquaporin-3.
2001 Jan 5
In vivo evidence for accelerated generation of hydroxyl radicals in liver of Long-Evans Cinnamon (LEC) rats with acute hepatitis.
2001 Mar 1
Reduced nephrotoxicity of conventional amphotericin B therapy after minimal nephroprotective measures: animal experiments and clinical study.
2002 Aug 1
Overexpression of copper zinc superoxide dismutase suppresses human glioma cell growth.
2002 Feb 15
NKCC activity restores muscle water during hyperosmotic challenge independent of insulin, ERK, and p38 MAPK.
2003 Mar
Synergistic effects of cystic fibrosis transmembrane conductance regulator and aquaporin-9 in the rat epididymis.
2003 May
Biochemistry. Water photolysis in biology.
2004 Mar 19
Molecular and functional characterization of a vasotocin-sensitive aquaporin water channel in quail kidney.
2004 Oct
Inherited sodium avid states.
2006 Apr
The renal medullary endothelin system in control of sodium and water excretion and systemic blood pressure.
2006 Jan
Mechanisms of disease: the role of GRK4 in the etiology of essential hypertension and salt sensitivity.
2006 Nov
Expression and functional characterization of four aquaporin water channels from the European eel (Anguilla anguilla).
2009 Sep 1
Aquaporins in the human testis and spermatozoa - identification, involvement in sperm volume regulation and clinical relevance.
2010 Aug 1
Beneficial effect of agmatine on brain apoptosis, astrogliosis, and edema after rat transient cerebral ischemia.
2010 Sep 6
Estrogen prevents increased hepatic aquaporin-9 expression and glycerol uptake during starvation.
2012 Feb 1
Effects of flavored mineral waters on AhR-CYP1A1 signaling pathway in primary human hepatocytes and in human hepatic and intestinal cancer cells.
2012 Jun
Investigation of the binding pocket of human hematopoietic prostaglandin (PG) D2 synthase (hH-PGDS): a tale of two waters.
2012 Jun 1
A novel aquaporin 3 in killifish (Fundulus heteroclitus) is not an arsenic channel.
2012 May
Copper(II)-human amylin complex protects pancreatic cells from amylin toxicity.
2013 Aug 14
Patents

Sample Use Guides

Suspension of this drug should be freshly prepared and not stored beyond 24 hours. The average daily adult dose of the resin is 15 g to 60 g. This is best provided by administering 15 g (approximately 4 level teaspoons) of Kayexalate one to four times daily. One gram of Kayexalate contains 4.1 mEq of sodium; one level teaspoon contains approximately 3.5 g of Kayexalate and 15 mEq of sodium (A heaping teaspoon may contain as much as 10 g to 12 g of Kayexalate). Since the in vivo efficiency of sodium-potassium exchange resins is approximately 33 percent, about one third of the resin’s actual sodium content is being delivered to the body.
Route of Administration: Oral
Parasagittal slices of cerebellum (250 mm) were prepared from male Wistar rat. Individual slices were viewed on a Zeiss FS Axioskop microscope with a 406water immersion objective and Nomarski differential interference optics, at a total magnification of 6406. Slices were maintained at 30–32uC and continuously perfused (1– 5 ml min21 ) with a CSF, which was bubbled with 95% O2 and 5% CO2. Whole-cell patch-clamp recordings were made from visualized Purkinje cells using an EPC 8 amplifier (Heka, Digitimer, Welwyn Garden City, UK) controlled via a Digidata 1322a interface (Axon Instruments INC, Foster City CA, USA) using Clampex (v 9, Axon Instruments). Patch-pipettes (thickwalled borosilicate glass, Harvard Apparatus, Edenbridge, UK) were fire-polished, and had resistances of 1.5–4 MV when filled with an intracellular solution containing (mM): 135 K gluconate, 7 NaCl, 10 HEPES, 0.5 EGTA, 2 Na2-ATP 0.3 Na2-GTP and 10 mM Na phosphocreatine (adjusted to pH 7.2 with KOH and osmolarity adjusted to 300 mOSM with sucrose). Aliquots of intracellular solution were stored frozen at 220uC and thawed on the day of recording.
Substance Class Chemical
Created
by admin
on Fri Dec 16 21:47:06 UTC 2022
Edited
by admin
on Fri Dec 16 21:47:06 UTC 2022
Record UNII
31R0R7HD0N
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
POTASSIUM SULFIDE
HSDB   INCI   MI   WHO-DD  
INCI  
Official Name English
DIPOTASSIUM MONOSULFIDE
Common Name English
POTASSIUM SULFIDE [INCI]
Common Name English
POTASSIUM SULPHIDE (2:1)
Common Name English
POTASSIUM SULFIDE [MI]
Common Name English
DIPOTASSIUM MONOSULPHIDE
Common Name English
POTASSIUM SULFIDE [HSDB]
Common Name English
POTASSIUM SULFIDE (2:1)
Common Name English
POTASSIUM MONOSULPHIDE
Common Name English
Potassium sulfide [WHO-DD]
Common Name English
POTASSIUM SULPHIDE
Common Name English
POTASSIUM MONOSULFIDE
Common Name English
Code System Code Type Description
MERCK INDEX
M9064
Created by admin on Fri Dec 16 21:47:06 UTC 2022 , Edited by admin on Fri Dec 16 21:47:06 UTC 2022
PRIMARY Merck Index
ECHA (EC/EINECS)
215-197-0
Created by admin on Fri Dec 16 21:47:06 UTC 2022 , Edited by admin on Fri Dec 16 21:47:06 UTC 2022
PRIMARY
WIKIPEDIA
POTASSIUM SULFIDE
Created by admin on Fri Dec 16 21:47:06 UTC 2022 , Edited by admin on Fri Dec 16 21:47:06 UTC 2022
PRIMARY
DAILYMED
31R0R7HD0N
Created by admin on Fri Dec 16 21:47:06 UTC 2022 , Edited by admin on Fri Dec 16 21:47:06 UTC 2022
PRIMARY
RXCUI
236907
Created by admin on Fri Dec 16 21:47:06 UTC 2022 , Edited by admin on Fri Dec 16 21:47:06 UTC 2022
PRIMARY RxNorm
FDA UNII
31R0R7HD0N
Created by admin on Fri Dec 16 21:47:06 UTC 2022 , Edited by admin on Fri Dec 16 21:47:06 UTC 2022
PRIMARY
EPA CompTox
DTXSID901014376
Created by admin on Fri Dec 16 21:47:06 UTC 2022 , Edited by admin on Fri Dec 16 21:47:06 UTC 2022
PRIMARY
EVMPD
SUB14996MIG
Created by admin on Fri Dec 16 21:47:06 UTC 2022 , Edited by admin on Fri Dec 16 21:47:06 UTC 2022
PRIMARY
HSDB
1204
Created by admin on Fri Dec 16 21:47:06 UTC 2022 , Edited by admin on Fri Dec 16 21:47:06 UTC 2022
PRIMARY
PUBCHEM
162263
Created by admin on Fri Dec 16 21:47:06 UTC 2022 , Edited by admin on Fri Dec 16 21:47:06 UTC 2022
PRIMARY
CAS
1312-73-8
Created by admin on Fri Dec 16 21:47:06 UTC 2022 , Edited by admin on Fri Dec 16 21:47:06 UTC 2022
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE